Showing 4881-4890 of 5646 results for "".
- Here Are the Specialties Hit Hardest by the COVID-19 Pandemichttps://modernod.com/news/here-are-the-specialties-hit-hardest-by-the-covid-19-pandemic/2479516/Health care revenue fell by nearly 50% in March and April for specialties that include primary care, oral surgery, dermatology and cardiology, a new study found, according to a FierceHealthcare
- ProQR Announces Expert Perspectives Conference Call Serieshttps://modernod.com/news/proqr-announces-expert-perspectives-conference-call-series/2479518/ProQR Therapeutics, a company dedicated to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, announced that it will launch a series of Expert Perspectives calls to provide an in-depth review of topics related to the company’s pipeline and
- US States Sue 26 Generic Drugmakers for Alleged Price Fixinghttps://modernod.com/news/us-states-sue-26-generic-drugmakers-for-alleged-price-fixing/2479522/A coalition of 51 US states and territories filed a lawsuit in federal court in Connecticut on Wednesday, accusing 26 drug companies, including Taro, Perrigo, Novartis’ Sandoz unit, Actavis, Mylan, Teva, G&W and Glenmark, of conspiring to fix prices and allocate markets for at least 80
- Implandata Launches Eyemate IOP-Tracking Service for Remote Monitoring and Improved Glaucoma Carehttps://modernod.com/news/implandata-launches-eyemate-iop-tracking-service-for-remote-monitoring-and-improved-glaucoma-care/2477870/Implandata Ophthalmic Products announced the launch of its web-based Eyemate IOP-Tracking Service for remote monitoring and management of glaucoma. The Eyemate provides eye doctors with IOP measurements collected anytime under patients’ normal life conditions. “Remote IOP monitoring provid
- Market Scope: Premium IOL Volume Faces Challenges in Rebounding Post-COVIDhttps://modernod.com/news/market-scope-premium-iol-volume-faces-challenges-in-rebounding-post-covid/2477871/Results from Part 1 of Market Scope’s “COVID-19 US Practice Impact Survey” reveal that nearly 41 percent of surgeons expect a decrease in premium IOL conversion once COVID-19 subsides. These surgeons expect an average decrease of 34 percent, and most respondents believe that financial
- The Lancet Withdraws Major Hydroxychloroquine Studyhttps://modernod.com/news/the-lancet-withdraws-controversial-hydroxychloroquine-study/2477866/A major study in the Lancet that suggested hydroxychloroquine was associated with higher rates of ventricular arrhythmia and death in COVID-19 patients has been retracted. The multinational registry analysis, published in the Lancet on May 22, included nearly 15,000 peopl
- Bausch + Lomb Receives FDA Clearance for Infuse Daily Disposable Silicone Hydrogel Contact Lenseshttps://modernod.com/news/bausch-lombs-infuse-daily-disposable-silicone-hydrogel-contact-lenses-receive-fda-510k-clearance-for/2477862/Bausch + Lomb has received 510(k) clearance from the FDA for the Bausch + Lomb Infuse daily disposable silicone hydrogel (SiHy daily) contact lenses. Bausch + Lomb Infuse contact lenses feature a next generation contact lens material (kalifilcon A), which is designed to meet the unmet need
- Re-vana Therapeutics Raises $3.25 Million in Pre-Series A Financinghttps://modernod.com/news/re-vana-therapeutics-raises-3-25-million-in-pre-series-a-financing/2477857/Re-Vana Therapeutics, a privately-held specialty therapeutic and drug delivery company developing sustained-release therapeutics for significant sight-threatening ocular diseases, announced that it has closed $3.25 mi
- Nicox Initiates First Phase 3 Trial of NCX 470 in Glaucomahttps://modernod.com/news/nicox-initiates-first-phase-3-trial-of-ncx-470-in-glaucoma/2477855/Nicox announced the initiation of the first phase 3 clinical trial, Mont Blanc, evaluating NCX 470 for the lowering of IOP in patients with open-angle glaucoma or ocular hypertension, by enrolling the first 12 patients. NCX 470 is the company’s novel, second-generation nitric oxide (NO)-donating
- Ocugen to Discontinue Phase 3 oGVHD Trialhttps://modernod.com/news/ocugen-to-discontinue-phase-3-ogvhd-trial/2477849/Ocugen announced the decision to discontinue the phase 3 trial of OCU300 for ocular Graft vs. Host Disease (oGVHD). The decision to stop the trial is based on results of a pre-planned interim sample size analysis conducted by an independent data monitoring committee, which indicated